Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer

Journal of Thoracic Oncology

Volumn 12, Issue 1, 2017, Pages 145-151

  Ou, Sai Hong Ignatius ^a   Govindan, Ramaswamy ^b   Eaton, Keith D ^c   Otterson, Gregory A ^d   Gutierrez, Martin E ^e   Mita, Alain C ^f   Argiris, Athanassios ^f   Brega, Nicoletta M ^g   Usari, Tiziana ^g   Tan, Weiwei ^g   Ho, Steffan N ^g   Robert, Francisco ^h,i  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Washington University in St Louis School of Medicine   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^f University of Texas Health Science Center at San Antonio   (United States)

^g PFIZER INC   (United States)

^h BIRMINGHAM VA MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Crizotinib; EGFR inhibitor; Erlotinib; MET inhibitor; Phase I combination trial

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CONCENTRATION TIME CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRY EYE; DRY SKIN; DYSPEPSIA; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; HYPOALBUMINEMIA; HYPOKALEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MUTATION; NAUSEA; NON SMALL CELL LUNG CANCER; NONSQUAMOUS NON SMALL CELL LUNG CANCER; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PUSTULAR RASH; RASH; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VISUAL IMPAIRMENT; VOMITING; WEIGHT REDUCTION; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; LYMPH NODE METASTASIS; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TISSUE DISTRIBUTION;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, PAPILLARY; ERLOTINIB HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRAZOLES; PYRIDINES; SURVIVAL RATE; TISSUE DISTRIBUTION;

EID: 85015276627     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.09.131     Document Type: Article

References (10)

1. 1 Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 23(3), 2011 75ra26.
2. 2 Kazandjian, D., Blumenthal, G.M., Chen, H.Y., et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 19 (2014), e5–e11.
3. 3 Kazandjian, D., Blumenthal, G.M., Luo, L., et al. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer. Oncologist 21 (2016), 974–980.
4. 4 Ou, S.H., Kwak, E.L., Siwak-Tapp, C., et al. Activity of crizotinib (PF02341066), a dual mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6 (2011), 942–946.
5. 5 Camidge, D.R., Ou, S.-H.I., Shapiro, G., et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). [abstract] J Clin Oncol, 32(suppl 5), 2014, 8001.
6. 6 Drilon, A.E., Camidge, D.R., Ou, S.-H.I., et al. Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). [abstract] J Clin Oncol, 34(suppl), 2016, 108.
7. 7 Tan, W., Wilner, K.D., Bang, Y., et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. [abstract] J Clin Oncol, 28(suppl 15), 2010, 2596.
8. 8 Rakhit, A., Pantze, M.P., Fettner, S., et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64 (2008), 31–41.
9. 9 Kwak, E.L., Bang, Y.J., Camidge, D.R., et al. Anaplastic lymphoma kinase inhibition in non-small cell lung cancer. N Engl J Med 363 (2010), 1693–1703.
10. 10 Yamazaki, S., Vicini, P., Shen, Z., et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 340 (2012), 549–557.